3-Ethenylbenzeneacetic acid | 107830-72-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Ethenylbenzeneacetic acid
• 英文别名: 2-(3-ethenylphenyl)acetic acid
• CAS: 107830-72-8
• 化学式: C₁₀H₁₀O₂
• 分子量: 162.18
• InChiKey: IDBTVFFCFJUWHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS DIHYDROPYRIMIDINE-2(1H)-ONES EN TANT QU'INHIBITEURS DE LA S-NITROSOGLUTATHION RÉDUCTASE
  申请人：N30 PHARMACEUTICALS LLC

  公开号：WO2011038204A1

  公开（公告）日：2011-03-31

  The present invention is directed to novel dihydropyrimidin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

  本发明涉及一种新型二氢嘧啶-2(1H)-酮化合物，可用作S-亚硝基谷胱甘肽还原酶（GSNOR）抑制剂，包括这些化合物的药物组合物，以及制备和使用这些化合物的方法。
• [EN] QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS<br/>[FR] QUINOXALINES ET AZA-QUINOXALINES COMME MODULATEURS DU RÉCEPTEUR CRTH2
  申请人：MERCK SHARP & DOHME

  公开号：WO2012087861A1

  公开（公告）日：2012-06-28

  The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J1, J2, R1, R2, R3, R22, Ra, Rb, Rc, Rd, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with with uncontrolled or inappropriate stimulation of CRTH2 function.

  该发明提供了式（I）中的某些喹喔啉和氮杂喹喔啉，以及它们的药用盐，其中J1、J2、R1、R2、R3、R22、Ra、Rb、Rc、Rd、X、Y、b、n和q如本文所定义。该发明还提供包含这些化合物的药物组合物，以及使用这些化合物治疗与CRTH2功能的不受控制或不适当刺激相关的疾病或症状的方法。
• Multi-branched polymer, process for producing the same, and applications thereof
  申请人：——

  公开号：US20040220346A1

  公开（公告）日：2004-11-04

  A group of polymers comprising a plurality of polyolefin chains and polar polymer chains and having a multi-branched structure such as a block structure, a graft structure and a star-shaped structure is produced efficiently by polymerizing or reacting a combination of various polar monomers and their polymers i.e. polar polymer chains by using a functional group-containing polyolefin as a macroinitiator, a macromonomer or a reactive polymer. The resulting multi-branched polymer has a specific shape such as a block structure, a graft structure or a star-shaped structure, and has properties of both the polyolefin and polar polymer, thus exhibiting useful performance in various uses in films and compatibilizing agents as a novel polyolefin-based polymer.

  通过使用含有功能性基团的聚烯烃作为宏启动剂、宏单体或反应性聚合物，聚合或反应各种极性单体及其聚合物即极性聚合物链，可以高效地生产出由多个聚烯烃链和极性聚合物链组成的聚合物群，其具有诸如块状结构、嫁接结构和星形结构等多分支结构。所得到的多分支聚合物具有特定形状，如块状结构、嫁接结构或星形结构，并具有聚烯烃和极性聚合物的性质，因此在薄膜和相容剂等各种用途中表现出有用的性能，是一种新型的基于聚烯烃的聚合物。
• Polyolefin macromonomer, graft polymer obtained from the polyolefin macromonomer, and use thereof
  申请人：——

  公开号：US20040242791A1

  公开（公告）日：2004-12-02

  A novel graft polymer useful in various uses that has a polyolefin backbone having polyolefin segments excellent in moldability can be obtained by homopolymerizing a novel polyolefin macromonomer or polymerizing the novel polyolefin macromonomer in the coexistence of other olefins depending on need, wherein the macromonomer has at the terminal of its polyolefin chain a vinyl group whose &agr;-position may be substituted, and the macromonomer can be efficiently obtained by a method, for example, successively carrying out i) a step of producing a polyolefin having a hydroxyl group at the terminal of the polyolefin chain and ii) a step of converting the terminal hydroxyl group of the polyolefin in chain into an acryloyl group, a methacryloyl group or a styryl group.

  一种新型的移植聚合物，可用于各种用途，具有聚烯烃骨架，其聚烯烃段具有优异的成型性能，可以通过聚合新型聚烯烃大分子单体或在需要时在其他烯烃的共存下聚合新型聚烯烃大分子单体来获得。其中，大分子单体在其聚烯烃链的末端具有一个乙烯基，其α-位可以被取代，通过一种方法可以高效地获得大分子单体，例如连续进行i）生成在聚烯烃链末端具有羟基的聚烯烃的步骤和ii）将聚烯烃的末端羟基转化为丙烯酰基、甲基丙烯酰基或苯乙烯基的步骤。
• Derivative having ppar agonistic activity
  申请人：Itai Akiko

  公开号：US20090286974A1

  公开（公告）日：2009-11-19

  A compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein Ring Q is optionally substituted monocyclic aryl, optionally substituted monocyclic heteroaryl, optionally substituted fused aryl or optionally substituted fused heteroaryl, Y 1 is a bond or —NR 6 — or the like, Ring A is optionally substituted nonaromatic heterocyclediyl, a group of the formula: -Y 2 Z 1 - is a group of the formula: R 7 are each independently hydrogen, optionally substituted lower alkyl or the like, R 8 and R 9 are each independently hydrogen or optionally substituted lower alkyl, n is an integer between 1 and 3, Z 1 is a bond, —O—, —S— or —NR 9 —, Ring B is optionally substituted aromatic carbocyclediyl or optionally substituted aromatic heterocyclediyl, Y 3 is a bond, optionally substituted lower alkylene optionally intervened by —O—, optionally substituted lower alkenylene or the like, and Z 2 is COOR 3 or the like.

  化合物的公式（I）：其药物可接受的盐或溶剂，其中环Q是可选择的取代的单环芳基，可选择的取代的单环杂芳基，可选择的融合芳基或可选择的融合杂芳基，Y1是键或-NR6-或类似物，环A是可选择的取代的非芳香杂环二基，公式组：-Y2Z1-是公式组：R7各自独立地是氢，可选择的取代的低烷基或类似物，R8和R9各自独立地是氢或可选择的取代的低烷基，n是1到3之间的整数，Z1是键，-O-，-S-或-NR9-，环B是可选择的取代的芳香碳杂环二基或可选择的取代的芳香杂环二基，Y3是键，可选择的取代的低烷基，可选择地介入-O-，可选择的取代的低烯基或类似物，并且Z2是COOR3或类似物。